United StatesIncluding Funding rounds, Bull / Bear thesis, Stock + earnings, Roster changes, Patents, News, and Open roles.
Already subscribed? Sign in →
Will Bruey is an aerospace engineer who earned a bachelor's degree in engineering physics and a master's in systems engineering from Cornell University. He joined SpaceX in 2012 as a hardware development engineer, working on Falcon 9 avionics and serving as a lead avionics engineer on the Dragon 1 and Dragon 2 spacecraft, and operated mission control consoles for Dragon through launch, rendezvous, and reentry. After meeting investor Delian Asparouhov and developing the concept of microgravity manufacturing-and-return, Bruey co-founded Varda Space Industries in 2020, where he serves as CEO building autonomous capsules that process pharmaceuticals in orbit and reenter Earth's atmosphere.
Delian Asparouhov is a venture investor and entrepreneur who is a partner at Founders Fund and the co-founder and president of Varda Space Industries. Before Founders Fund he was a principal at Khosla Ventures, head of growth at the apparel company Teespring, and founder of the healthcare startup Nightingale. Varda was incubated within Founders Fund, where Asparouhov developed the idea of in-space manufacturing and recruited SpaceX engineer Will Bruey to build it; he co-founded the company in 2020 and continues to serve as president alongside his investing role.
Trae Stephens earned a degree in Regional and Comparative Studies focused on the Middle East from Georgetown University's School of Foreign Service, then worked as a computational linguist in the US intelligence community before joining Palantir Technologies as an early employee in 2008, where he led defense and intelligence business expansion. He became a partner at Founders Fund in 2014, focusing on government and defense technology investments, and in 2017 co-founded the defense company Anduril Industries with Palmer Luckey, where he serves as executive chairman. In 2020 he co-founded Varda Space Industries alongside Delian Asparouhov and Will Bruey, backing its in-orbit manufacturing thesis.
No articles ingested yet for Varda Space Industries. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
Autonomous orbital manufacturing and return vehicles that process pharmaceuticals and materials in microgravity then reenter Earth's atmosphere and land on demand. Varda has flown a growing cadence of missions, with W-5 and W-6 both completing successful reentries in 2026 — W-6 landing at the Koonibba Test Range in South Australia and validating autonomous navigation and advanced thermal-protection systems. Each capsule carries Air Force Research Laboratory hypersonic-reentry payloads alongside commercial pharmaceutical experiments, making Varda a dual-use defense reentry testbed and commercial drug manufacturer simultaneously.
Integrated microgravity processing system that crystallizes small-molecule drugs and biologics—including monoclonal antibodies—in orbit, where the absence of gravity enables superior crystal uniformity and purity versus Earth-based production. Varda's first client, Improved Packing for Proteins (ritonavir experiments), demonstrated pharmaceutical-grade results. A $187M Series C in 2025 scaled operations toward a recurring cadence of reentries, cementing Varda as the first commercial in-space factory.
2 patents on file, but none with both an extractable figure and an abstract on Google Patents yet.
